New Study Published in JCO Precision Oncology Shows Myriad Genetics‘ Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer

LabNews Media LLC
2024-05-17
Aktuelles

Myriad’s Prolaris Test is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1
New Study Published in JCO Precision Oncology Shows Myriad Genetics‘ Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer

LabNews Media LLC

The Editors in Chief of lab-news.de are Marita Vollborn and Vlad Georgescu. They are bestselling authors, science writers and science journalists since 1994.More details about their writing on X-Press Journalistenbüro (https://xpress-journalisten.com).More Info on Wikipedia:About Marita: https://de.wikipedia.org/wiki/Marita_Vollborn About Vlad: https://de.wikipedia.org/wiki/Vlad_Georgescu

New Study Published in JCO Precision Oncology Shows Myriad Genetics‘ Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer

LabNews Media LLC

Stay Connected

Unmatched reporting

New Study Published in JCO Precision Oncology Shows Myriad Genetics‘ Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer

LabNews Media LLC

Ähnliche Beiträge

Wissenschaftliche Evidenz zum Hautkrebs-Screening in Deutschland

Editorial: Backhaus’ fortgesetzte Verletzung der Garantenpflicht

Blockchain erobert die Biomedizin

Stay Connected

Unmatched reporting